Tema Oncology ETF
CANC
3 hedge funds and large institutions have $13.2M invested in Tema Oncology ETF in 2024 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 3 closing their positions.
1.01% more ownership
Funds ownership: 25.84% → 26.85% (+1%)
4% more capital invested
Capital invested by funds: $12.6M → $13.2M (+$536K)
40% less funds holding
Funds holding: 5 → 3 (-2)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
+$3.21M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$54 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$1.26M |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
-$5.68K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$3K |
CANC Hedge Fund Activity: Q4 2024 in Review
3 of the 7,600 institutional investors tracked by Wall St. Rank reported a position in Tema Oncology ETF (CANC) for Q4 2024, worth a combined $13.2M — up 4.2% from $12.6M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of CANC and 1 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 1 added.
The largest buyer was Thrivent Financial for Lutherans, adding an estimated $3.21M. The largest seller was Jane Street, exiting entirely with an estimated $1.26M sold.
- 3 institutional investors held Tema Oncology ETF (CANC) as of Q4 2024, down from 5 in Q3 2024.
- Funds reported $13.2M of Tema Oncology ETF stock for Q4 2024, up 4.2% quarter-over-quarter.
- 1 fund opened new Tema Oncology ETF positions in Q4 2024 and 3 closed out, a net change of -2 holders.
- The largest Tema Oncology ETF buyer in Q4 2024 was Thrivent Financial for Lutherans, an estimated $3.21M added.
- The largest Tema Oncology ETF seller in Q4 2024 was Jane Street, an estimated $1.26M sold.
Based on aggregated 13F filings for Q4 2024.